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DNA damagea b s t r a c t
Nucleostemin is a nucleolar protein known to play a variety of roles in cell-cycle progression, apoptosis
inhibition, and DNA damage protection in embryonic stem cells and tissue stem cells. However, the role
of nucleostemin in hematopoietic stem cells (HSCs) is yet to be determined. Here, we identiﬁed an indis-
pensable role of nucleostemin in mouse HSCs. Depletion of nucleostemin using short hairpin RNA strik-
ingly impaired the self-renewal activity of HSCs both in vitro and in vivo. Consistently, nucleostemin
depletion triggered apoptosis rather than cell-cycle arrest in HSCs. Furthermore, DNA damage accumu-
lated during cultivation upon depletion of nucleostemin. The impaired self-renewal activity of HSCs
induced by nucleostemin depletion was partially rescued by p53 deﬁciency but not by p16Ink4a or
p19Arf deﬁciency. Taken together, our study demonstrates that nucleostemin protects HSCs from DNA
damage accumulation and is required for the maintenance of HSCs.
 2013 The Authors. Published by Elsevier Inc.  Open access under CC BY-NC-ND license.1. Introduction homeostasis in the hematopoietic system [7,8]. However, muchHematopoietic stem cells (HSCs) reside at the apex of the blood
system hierarchy. HSCs can give rise to daughter stem cells by self-
renewal and also to multipotent progenitors (MPPs) by differenti-
ation, which in turn give rise to a variety of committed progenitors
and mature blood cells. HSCs preserve homeostasis by serving as a
lifelong source of blood cells. As such, any mis-repair of DNA dam-
age can be transmitted to their daughter cells [1], and accumula-
tion of DNA damage in the HSC pool can result in decreased
regenerative capacity—one of the physiological hallmarks of
aging—or the development of hematological malignancies upon
acquisition of oncogenic mutations [2]. Therefore, the HSC genome
must be strictly protected from various genotoxic insults such as
ionizing radiation [3], reactive oxygen species [4], endogenous
metabolites [5], and replicative stress [6]. HSCs use complex mech-
anisms to maintain their genome integrity, including DNA repair,
transient cell-cycle arrest, senescence, and apoptosis [1], and there
is growing evidence to support apoptosis as an important mecha-
nism for controlling the quality of the HSC pool and maintainingremains to be clariﬁed regarding how stem cells manage DNA
damage to maintain the homeostatic balance while avoiding aging
or cancer development.
Nucleostemin is a GTP-binding protein present in the nucleoli of
neural stem cells, embryonic stem cells (ESCs), other stem cell-
enriched populations such as hematopoietic stem and progenitor
cells, and also several cancer cell lines [9,10]. The importance of
nucleostemin in stem cells is emphasized by the fact that deletion
of nucleostemin in mouse ESCs causes failure to enter S-phase, in-
creased senescence and apoptosis, and eventually embryonic death
at the blastocyst stage [11–13]. The evidence that nucleostemin
can directly associate with p53 raises the possibility that nucleos-
temin regulates the activity of p53 [14]. However, because loss of
p53 does not rescue nucleostemin-null mice from embryonic
lethality, nucleostemin appears to regulate stem cell fate via other
mechanisms. Recent studies have revealed that nucleostemin
prevents DNA damage accumulation and subsequent proliferation
defects caused by telomere dysfunction [15] and replicative stress
[16,17]. In addition to its role in normal stem cells, abundant
expression of nucleostemin is also critical for the maintenance of
cancer stem cells [18]. In this respect, nucleostemin is a key regu-
lator in both normal and cancer stem cells. Therefore, a better
understanding of the role of nucleostemin in stem cells will
provide an important insight into the molecular mechanism
underlying ‘stemness’. However, the role of nucleostemin has yet
to be explored in HSCs, for which stem cell activity can be precisely
evaluated using established experimental systems.
M. Yamashita et al. / Biochemical and Biophysical Research Communications 441 (2013) 196–201 197Here, we investigated the role of nucleostemin in HSCs. We
evaluated the effect of nucleostemin depletion in HSCs/MPPs by
phenotypic and functional analyses following nucleostemin knock-
down with a short hairpin RNA (shNS). We show that nucleostemin
is indispensable for HSC self-renewal. Nucleostemin plays an
essential role in maintaining the genetic stability and cell viability
of HSCs/MPPs in the proliferative state, which is to some extent
dependent on p53 but not on p16Ink4a or p19Arf. These results re-
veal how nucleostemin contributes to the maintenance of HSC
activity.
2. Materials and methods
2.1. Mice
C57BL/6 mice (Ly5.1 and Ly5.2) were purchased from Sankyo
Labo Service (Tokyo, Japan). To obtain p53-null hematopoietic
cells, Mx1-Cre; p53ﬂox/ﬂox mice, generated by crossing p53ﬂox/ﬂox
mice [19] and Mx1-Cre mice [20], were intraperitoneally adminis-
tered with 400 lg pIpC (Sigma–Aldrich, St. Louis, MO, USA) ﬁve
times every other day at least 4 weeks before collecting bone mar-
row. The p16Ink4a/p19Arf/ mice were described previously [21].
All procedures in this study were performed in accordance with
the guidelines for animal and recombinant DNA experiments of
Keio University School of Medicine, with the approval of the insti-
tutional review board of Keio University.Fig. 1. Expression of nucleostemin in hematopoietic cells. (A) qRT-PCR analysis of nucleo
erythroid cells (Ter119+), myeloid cells (Gr1+Mac1+), B cells (B220+CD19+), T cells (CD3
GMPs (LinSca1cKit+CD34+FccRII/IIIhigh), CMPs (LinSca1cKit+CD34+FccRII/IIIlow), MP
from adult murine bone marrow are shown (n = 3). (B) Immunocytochemistry of nucleos
(green), co-immunostained in the hematopoietic cells described above. Nuclei were count
cells, and T cells, respectively. NS: nucleostemin, Fib: ﬁbrillarin.2.2. Antibodies for ﬂow cytometry
The antibodies used for ﬂow cytometry and cell isolation are
listed in Supplementary Table S1. A cocktail of monoclonal anti-
bodies against CD4, CD8, B220, Ter119, Gr-1, and Mac-1 was used
to identify lineage+ cells.
2.3. Flow cytometric analysis and isolation of hematopoietic cells
Bone marrow cells were collected frommouse femurs and tibias
for analysis and isolation of HSCs. The methods used to isolate
HSCs and other hematopoietic cells were described previously
[22]. Cell-cycle analysis using a monoclonal anti-Ki67 antibody
was performed as described previously [23]. For apoptosis detec-
tion, cells stained for cell surface markers were further incubated
for 15 min with APC-conjugated Annexin V (BD Biosciences, San
Jose, CA, USA) and DAPI (Molecular Probes, Eugene, OR, USA)
according to the manufacturer’s instructions. All data collection
was performed on FACS Calibur or FACS Aria II instruments (BD
Biosciences) and data were analyzed with FlowJo software
(Treestar, Ashland, OR, USA).
2.4. Retroviral transduction
shRNA sequences targeting nucleostemin (#1: GTAAGAAGC
TGATACTTGTAT, #2: GGAGTAAGAAGCTGATACTTG) were clonedstemin in various hematopoietic cells. Relative expression levels of nucleostemin in
+), CLPs (LinSca1lowcKitlowFlt3+IL-7Ra+), MEPs (LinSca1cKit+CD34FccRII/IIIlow),
Ps (CD150LinSca1+cKit+), and HSCs (CD150+CD41CD48LinSca1+cKit+) sorted
temin in hematopoietic cells. Nucleostemin (red) and a nucleolar marker, ﬁbrillarin
erstained with DAPI (blue). Er, My, B, and T represent erythroid cells, myeloid cells, B
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transfected into Plat-E cells with FuGENE HD (Roche Diagnostics
GmbH, Mannheim, Germany), and the supernatant was used as
the retrovirus solution. Retroviral transduction of lineage Sca1+
cKit+ (LSK) cells was performed on RetroNectin (Takara Bio, Otsu,
Japan) using Magnetofection (OZ Biosciences, Marseille, France),
as described previously [25].
2.5. Bone marrow transplantation
LSK cells from C57BL/6-Ly5.1 congenic mice were isolated and
subjected to retroviral transduction as described above. Two days
later, 5000 GFP+ LSK cells were isolated by FACS and transplanted
into 9.5 Gy-irradiated C57BL/6 mice (Ly5.2) together with 4  105
BM MNCs from C57BL/6 mice (Ly5.2). The reconstitution of
donor-derived cells was monitored by staining peripheral blood
samples with monoclonal antibodies against Ly5.1 and Ly5.2 every
4 weeks. The chimerism of BM was analyzed 4 months after
transplantation.
2.6. Colony assay
Two hundred transduced GFP+ LSK cells were plated in 1 ml of
methylcellulose medium (Methocult GF M3434; StemCell Technol-
ogies, Vancouver, Canada) on 35-mm petri dishes in triplicate.
Colony-forming units in culture (CFU-C) and high proliferative
potential-colony forming cells (HPP-CFC) were scored on days 10
and 14 of culture, respectively.
2.7. Immunocytochemistry
Sorted LSK cells were placed onto a glass slide, ﬁxed with
ice-cold methanol followed by ice-cold acetone, and stained with
anti-nucleostemin (R&D Systems, Minneapolis, MN, USA; 2.5 lg/mL),Fig. 2. Colony formation and bone marrow reconstitution capacity of HSCs after nucleo
shRNA or shNS. Representative images of colonies formed in methylcellulose (upper) and
shown (n = 3). (B and C) Competitive bone marrow transplantation using LSK cells transd
for shNS#2). 5000 Ly5.1+ transduced LSK cells were transplanted into lethally irradiate
percentages of donor-derived (Ly5.1+) cells were examined every 4 weeks in peripheralanti-ﬁbrillarin (Abcam, Cambridge, UK; 5 lg/mL), and anti-53BP1
(Novus Biologicals, Littleton, CO, USA; 5 lg/mL) antibodies. Nuclei
were identiﬁed by staining with DAPI (Molecular Probes). Images
were collected using a FV1000 confocal laser-scanning microscope
and FV10-ASW software Version 2.0 (Olympus, Tokyo, Japan).
2.8. Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
Total RNA was obtained using the RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s protocol. cDNA
was synthesized using Superscript III reverse transcriptase and
random hexamer primers (Invitrogen, Carlsbad, CA, USA). qRT-PCR
was performed using 2 Fast Universal master mix and TaqMan
Gene Expression Assays (Applied Biosystems, Foster City, CA,
USA). Sample RNA content was normalized based on b-actin
ampliﬁcation.
2.9. Statistical analysis
An unpaired two-tailed Student’s t-test was used for compari-
sons between the two groups. Data are shown as the means ± S.D.
⁄P < 0.05 was considered as signiﬁcant, and ⁄⁄P < 0.01 as highly
signiﬁcant.3. Results
3.1. Nucleostemin is abundantly expressed in hematopoietic stem and
progenitor cells
The expression of nucleostemin was reported to be enriched in
Sca1+, AA4.1+, c-kit+ fetal liver hematopoietic stem cells [26], and
adult LincKit+ cells [9]. To further examine the expression ofstemin depletion. (A) CFU-C assay using 200 LSK cells transduced with scrambled
a stacked bar graph indicating the number of colonies in each category (lower) are
uced with scrambled shRNA or shNS (n = 6 for scrambled shRNA and shNS#1; n = 3
d recipient mice (Ly5.2) together with 4  105 competitor BM MNCs (Ly5.2). The
blood (B) and at 16 weeks post-transplantation in bone marrow (C).
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etic cells from adult mouse bone marrow and evaluated the
expression of nucleostemin by qRT-PCR (Fig. 1A). Consistent with
previous reports, nucleostemin was highly expressed in LincKit+
immature hematopoietic cells such as MEPs, GMPs, CMPs, MPPs,
and HSCs. Immunocytochemical analysis revealed that nucleoste-
min was predominantly expressed in the nucleoli by co-immuno-
staining with the nucleolar marker, ﬁbrillarin (Fig. 1B). These
results suggest that nucleostemin is abundantly expressed in
immature hematopoietic cells, including HSCs.
3.2. Nucleostemin is indispensable for the maintenance of HSCs
To assess the function of nucleostemin in HSCs, we evaluated
the effect of nucleostemin depletion in HSCs. Retroviruses carrying
shRNA against nucleostemin (shNS) were prepared, and an approx-
imate 50% reduction in endogenous nucleostemin mRNA expres-
sion was observed following transduction with shNS#1 and
shNS#2 (Supplementary Fig. S1A). The level of nucleostemin pro-
tein was also efﬁciently reduced (Supplementary Fig. S1B). Using
these retroviruses, LSK cells, which consist of HSCs and MPPs, were
transduced with scrambled shRNA or shNS, and colony formation
assays were performed. Nucleostemin was successfully down-reg-
ulated after the transduction of shNS (Supplementary Fig. S1C), and
the colony-forming capacity of nucleostemin-depleted LSK cells
was signiﬁcantly decreased as measured by CFU-C and HPP-CFC as-
says (Fig. 2A and Supplementary Fig. S1D). Consistent with these
results, the long-term reconstitution capacity was strikingly
impaired in nucleostemin-depleted LSK cells (Fig. 2B and C). TheseFig. 3. Cell cycle and apoptosis in HSCs after nucleostemin depletion. Flow cytometric ana
33347 (A), and Annexin V and DAPI (B) staining. Representative plots (left) and the percresults demonstrate an indispensable role of nucleostemin for the
maintenance of HSCs.
3.3. Depletion of nucleostemin triggers apoptosis in HSCs
Depletion of nucleostemin can induce cell-cycle arrest and/or
apoptosis in ESCs and tissue stem cells [13,27], although this effect
of nucleostemin has not yet been documented in HSCs. We there-
fore analyzed cell-cycle status and apoptosis in LSK cells 2 days
after transduction with scrambled shRNA or shNS. Despite the sig-
niﬁcant reduction in proliferation and self-renewal capacity, LSK
cells treated with shNS did not show major changes in cell cycle
status as shown by Ki67 staining (Fig. 3A). A BrdU short labeling as-
say revealed that the population of cells in S-phase was compara-
ble or slightly increased, suggesting that entry into S-phase was
not disturbed by the depletion of nucleostemin (data not shown)
and that cell-cycle arrest is not a main cause for the reduction of
proliferation and self-renewal capacity. Instead, the percentage of
apoptotic cells was signiﬁcantly elevated in nucleostemin-
depleted LSK cells (Fig. 3B), and the rate of apoptosis was inversely
related to the colony-forming capacity and bone marrow reconsti-
tution capacity. These results indicate that nucleostemin depletion
induces apoptosis rather than cell-cycle arrest, thereby reducing
the self-renewal capacity of HSCs.
3.4. Nucleostemin depletion induces DNA damage accumulation
Apoptosis can be induced by various cellular stresses, including
DNA damage, and proliferation can be accompanied by replicativelysis of LSK cells transduced with scrambled shRNA or shNS using Ki67 and Hoechst
entages of cells in each state (right) are shown (n = 3).
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accumulation [28]. Recently, it was reported that deletion of nucle-
ostemin induces cH2AX foci in neural stem cells [16] and hepato-
cyte progenitor cells [17] during proliferation. To assess the
possibility that nucleostemin also prevents DNA damage in HSCs,
we examined the accumulation of 53BP1, another marker of the
DNA damage response, in LSK cells 2 days after transduction with
scrambled shRNA or shNS. Consistently, nucleostemin-depleted
LSK cells showed a remarkable increase in the number of 53BP1
foci (Fig. 4A). Meanwhile, we observed signiﬁcant up-regulation
of p21 and Bax mRNAs in nucleostemin-depleted LSK cells (data
not shown), indicating that nucleostemin reduction causes DNA
damage in HSCs, which induces apoptosis and reduces the self-re-
newal capacity as a result.
3.5. HSC impairment induced by nucleostemin depletion is partly
mediated by p53 but not by p16Ink4a/p19Arf
Following induction of DNA damage, distinct factors detect,
transmit, and amplify the DNA damage signal. This DNA damage
response (DDR) converges on p53, which regulates different cellu-
lar outcomes depending on the target genes activated, such as p21
for transient cell-cycle arrest, Bax, Puma, and Noxa for apoptosis,
and p16Ink4a and p19Arf for senescence [1]. To assess whether the
reduction of self-renewal capacity by nucleostemin depletion is
mediated through the activation of p53 or p16Ink4a/p19Arf, we
introduced shNS into p53D/D or p16Ink4/p19Arf/ LSK cells. Inter-
estingly, depletion of nucleostemin still reduced colony forming
activity in the absence of p53 or p16Ink4a/p19Arf (Fig. 4B and
Supplementary Fig. S2A and B), although loss of p53 partially
rescued the reduction of colony formation capacity (Fig. 4C). These
results demonstrate that reduction of the self-renewal capacity of
HSCs by nucleostemin depletion is partly mediated through the
activation of p53, but not through p16Ink4a/p19Arf.Fig. 4. DNA damage response in nucleostemin-depleted HSCs. (A) Immunocytochem
Representative images (upper) and a boxplot of 53BP1 foci per nucleus (lower) are show
transduced with scrambled shRNA or shNS. The number of colonies classiﬁed into eac
transduced with shNS to the total number of colonies formed by LSK cells transduced w4. Discussion
We ﬁrst established direct evidence that nucleostemin is essen-
tial for HSC self-renewal. Our ﬁndings indicate that nucleostemin
protects HSCs from genotoxic insults and subsequent apoptosis,
thereby maintaining cell viability. Because the expression of nucle-
ostemin is comparably high in committed progenitor cells with
limited differentiation but high proliferation potential (Fig. 1A
and B), and because differentiation capacity is not altered after
nucleostemin reduction (Fig. 2C), it seems that the function of
nucleostemin might be associated with proliferation. Proliferation
essentially accompanies replicative stress, one of the intrinsic
sources of DNA damage, and indeed nucleostemin plays an impor-
tant role in preventing DNA damage accumulation during short-
term culture when cells are enforced to proliferate with cytokines
(Fig. 4A).
The observation that the depletion of nucleostemin causes DNA
damage in proliferating HSCs/MPPs is quite consistent with recent
studies suggesting that DNA damage accumulates in neural stem
cells and hepatocyte progenitor cells after conditional deletion of
nucleostemin [17,19]. Regarding the underlying mechanisms,
there is emerging evidence that nucleostemin recruits RAD51, a
key molecule for homologous recombination in mammals, to
DNA lesions [15,17,19]. TERT can associate with nucleostemin
[15,18], and we have previously shown that TERT prevents HSCs
from DNA damage and subsequent apoptosis following reactive
oxygen species stress [23]. Considering both ﬁndings, nucleoste-
min may play a signiﬁcant role in the genetic stability of the telo-
meric region in collaboration with TERT.
Damaged cells may undergo transient cell-cycle arrest, senes-
cence, or apoptosis, depending on the extent, type, and duration
of DNA damage. Following the massive accumulation of 53BP1 foci
in the nuclei after nucleostemin depletion, apoptosis rather than
cell-cycle arrest appeared to function as a compensatoryical staining of 53BP1 in LSK cells transduced with scrambled shRNA or shNS.
n (n = 100). (B and C) CFU-C assay using p53D/D and p16Ink4a/p19Arf/ LSK cells
h category (B) and the ratio of the total number of colonies formed by LSK cells
ith scrambled shRNA (C) are shown (n = 3).
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(Fig. 3B). In the present study, the decreased number of CFU-C
caused by nucleostemin depletion was partially rescued by p53
deﬁciency but not by p16Ink4a or p19Arf deﬁciency (Fig. 4B), indicat-
ing that nucleostemin depletion triggers apoptosis and diminishes
HSC self-renewal partly through the activation of p53.
In conclusion, our present study established a vital role for
nucleostemin in the maintenance of HSCs. Nucleostemin makes a
signiﬁcant contribution to the conservation of genetic stability in
HSCs. Because nucleostemin is preferentially expressed in stem
cells, is localized in nucleoli, and regulates genetic stability, further
investigation into its molecular function will enable a better
understanding of how stem cells use their nucleoli to manage
DNA damage for the maintenance of self-renewal and to avoid pre-
mature aging and cancer development.
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